Search | Clinical Trials Finder

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:29 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2497–2520 of 4,251 matching trials from the local directory fallback.

Filters: Intervention: Placebo Clear all

Conditions: Inflammatory Bowel Diseases
Interventions: LpD3.5 supplementation., Placebo; Dietary Supplement
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: THC
Interventions: Placebo, THC; Other · Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Myocardial Infarction
Interventions: Dapansutrile, Placebo; Drug · Other
Lead sponsor: University of Virginia; Other
Eligibility: 25 Years to 99 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Acute Kidney Injury
Interventions: Amino Acids, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 1 Day to 18 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Sickle Cell Disease
Interventions: L-citrulline, Placebo; Drug · Other
Lead sponsor: Asklepion Pharmaceuticals, LLC; Industry
Eligibility: 6 Years to 21 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Coral Gables, Florida • Atlanta, Georgia + 3 more

Conditions: Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS)
Interventions: Debamestrocel - MSC-NTF (NurOwn), Placebo; Biological
Lead sponsor: Brainstorm-Cell Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 15
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 11 more

Conditions: Alzheimer's Disease
Interventions: Placebo Comparator, T3D-959; Other · Drug
Lead sponsor: T3D Therapeutics, Inc.; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 376 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Hernia, Ventral, Pain Management
Interventions: Placebo, Quadratus Lumborum (QL) Block; Procedure
Lead sponsor: University of Tennessee Graduate School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Upper Extremity Bone Pain, Upper Extremity Muscle Pain, Upper Extremity Pain
Interventions: Cannabidiol (CBD), Placebo; Drug
Lead sponsor: Brent DeGeorge; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Pharmacodynamics, Pharmacokinetics, Safety Issues, Tolerability
Interventions: AVR-48, Placebo; Drug
Lead sponsor: AyuVis Research, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Essential Tremor
Interventions: GyroGlove, Placebo; Device
Lead sponsor: GyroGear Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 3
States / cities: Farmington Hills, Michigan • Houston, Texas • Burlington, Vermont

Conditions: Arthroscopic Hip Repair, Arthroscopic Knee Repair
Interventions: Methadone group, Placebo; Drug
Lead sponsor: Keck School of Medicine of USC; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Endothelial Dysfunction, Endothelial Function (reactive Hyperemia), Ischemic Preconditioning, Metabolic Syndrome, Vascular Injury
Interventions: Intravenous lactate infusion, Ischemic preconditioning, Ischemic preconditioning and intravenous lactate, No ischemic preconditioning (control), Normal Saline Infusion (Placebo); Drug · Procedure · Combination Product
Lead sponsor: Gary Van Guilder; Other
Eligibility: 18 Years to 65 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Gunnison, Colorado

Conditions: Antibiotic Prophylaxis, Dysbiosis, Gut -microbiota, Microbiome Analysis, Probiotic
Interventions: Placebo Capsule, Probiotic with Human Milk Oligosaccharides (HMO); Drug · Dietary Supplement
Lead sponsor: Acibadem Maslak Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Alcohol, Alcohol Consumption, Hangover Symptoms, NAC, Veisalgia
Interventions: Placebo, Supplement; Dietary Supplement
Lead sponsor: Medical Life Care Planners, LLC; Other
Eligibility: 21 Years and older
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: St. Petersburg, Florida

Conditions: Benign Prostatic Hyperplasia
Interventions: Placebo, Tranexamic Acid (IV); Drug
Lead sponsor: Kaiser Permanente; Other
Eligibility: 45 Years and older · Male only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Amino Acid Absorption, Probiotic
Interventions: Placebo + Milk Protein, Single Strain Probiotic + Milk Protein; Dietary Supplement
Lead sponsor: The Archer-Daniels-Midland Company; Industry
Eligibility: 18 Years to 35 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Belton, Texas

Conditions: Antibiotics, Neurodevelopment, Premature Birth
Interventions: Ampicillin, Gentamicin, Placebo; Drug
Lead sponsor: Sharp HealthCare; Other
Eligibility: 23 Weeks to 30 Weeks
Enrollment: 802 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 14
States / cities: San Diego, California • New Haven, Connecticut • Tampa, Florida + 9 more

Conditions: Type 2 Diabetes Mellitus (T2DM)
Interventions: ALN-4324, Placebo; Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Early Alzheimers Disease
Interventions: Placebo, buntanetap/posiphen; Drug
Lead sponsor: Annovis Bio Inc.; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 760 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 78
States / cities: Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 72 more

Conditions: Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)
Interventions: Maralixibat, Placebo; Drug · Other
Lead sponsor: Mirum Pharmaceuticals, Inc.; Industry
Eligibility: 6 Months and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 8
States / cities: Los Angeles, California • Palo Alto, California • Chicago, Illinois + 4 more

Conditions: Prurigo Nodularis
Interventions: Placebo, Povorcitinib; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 346 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 28
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Fountain Valley, California + 24 more

Conditions: Cerebral Amyloid Angiopathy
Interventions: ALN-APP, Placebo; Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 30 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 34
States / cities: Los Angeles, California • Orange, California • Palo Alto, California + 27 more

Conditions: Type 2 Diabetes
Interventions: Placebo, Retatrutide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 28
States / cities: Huntsville, Alabama • Sun City West, Arizona • Apple Valley, California + 24 more

Search by objective public record fields.

Impact of a Human Origin Heat Inactivated Probiotic-Lactobacillus Paracasei D3.5 (LpD3.5) as Dietary Supplement on Gut Mucin and Intestinal Permeability in Adults With IBD

Multimodal Magnetoencephalography and Electroencephalography Exploration of the Acute Effects of THC Exposure on Neural Noise and Information Transmission Within Working Memory Networks

Multimodality Cardiovascular Imaging for the Translation of Therapies for Vascular Activation After MI

Amino Acids for Cardiac Surgery Associated AKI

A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis

Efficacy and Safety of MSC-NTF (NurOwn) in Participants With Early Symptomatic ALS and Moderate Disease Presentation in ALS (ENDURANCE STUDY)

A Phase 2b/3 Clinical Study Evaluating T3D-959 in Mild-to-Moderate Alzheimer's Disease Subjects

Quadratus Lumborum Versus Placebo in Open Ventral Hernia Repair

A Randomized Controlled Trial of Oral CBD for the Treatment of Upper Extremity Musculoskeletal Pain

Single Ascending Dose and Multiple Ascending Dose Study of AVR-48

GyroGlove Use in Essential Tremor Patients

PO Methadone Ortho Outpatient

Therapeutic Strategies to Reduce Endothelial Ischemia-reperfusion Injury

Impact of Probiotics on Gut Microbiome During Antibiotic Prophylaxis in Elective Orthopedic Surgery

Rapid BAC Reduction with Nutraceutical Blend Study

Effect of Tranexamic Acid on Intraoperative Blood Loss in Patients Undergoing Aquablation

Changes in Amino Acid Absorption After Adding a Probiotic to an Acute Protein Feeding

NICU Antibiotics and Outcomes (NANO) Follow-up Study

A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus

A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD

Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)

A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy

Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)